Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Neurogenetic Testing Market In 2029?

The neurogenetic testing market has experienced a swift surge in recent years. The market size will expand from a size of $0.61 billion in 2024 to $0.7 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.9%. This significant growth during the historic period can be accredited to factors such as a heightened incidence of neurological diseases, increased life science research, a rising prevalence of Parkinson’s disease, a growth in cancer cases and an increase in consciousness among healthcare professionals.

What Growth Rate Is Forecasted for the Neurogenetic Testing Market by 2029?

The market size for neurogenetic testing is predicted to considerably expand in the coming years, with anticipated growth to a value of $1.16 billion by 2029, and a compound annual growth rate (CAGR) of 13.5%. The forecasted growth can be linked to the proliferation of personalized medicine applications, the prevalence of chronic diseases, an uptick in hospitals and diagnostic laboratories, and an intensified focus on early disease detection. Key trends for this forecast period involve technological advancements, increased uptake of non-invasive testing procedures, the development of new products, strategic partnerships, and the rise of innovative biomarkers related to neurological disorders.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Key Companies Are Shaping the Future of the Neurogenetic Testing Market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Which Factors Are Driving Demand in the Neurogenetic Testing Industry?

The neurogenetic testing market is poised for growth, spurred on by the increasing incidence of neurological disorders. These disorders, affecting the brain, spinal cord, and nerves, can be attributed to genetic predisposition, trauma, toxins, infections, autoimmune reactions, and degeneration. Neurogenetic testing is a powerful tool in diagnosing, managing, and treating these disorders as it offers personalized genetic risk assessments, informing treatment plans and enabling patients and families to make knowledgeable health decisions, which enhances patient care and outcomes. For instance, the Belgium-based non-profit organization, the European Brain Council, reported in April 2022, that there are currently over 600 neurological diseases and close to 300 psychiatric conditions affecting millions worldwide, including 65 million with epilepsy. Additionally, in Europe, there are currently 10.5 million people suffering from dementia, a number predicted to increase to 18.7 million by 2050. Hence, this increase in neurological disorders is anticipated to fuel the growth of the neurogenetic testing market.

Neurogenetic Testing Market Driver: Surging Cancer Cases Fosters Expansion of Neurogenetic Testing Market

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

How Is the Neurogenetic Testing Market Segmented by Several Divisions?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

What are the Emerging Market Trends Driving the Growth of the Neurogenetic Testing Industry?

Prominent businesses in the neurogenetic testing market are focusing on the advancement of novel products, such as whole-genome sequencing, to boost the precision and extent of genetic examination, thereby promoting exhaustive and customized testing for neurological diseases. Whole-genome sequencing (WGS) is an all-encompassing genetic examination method, which involves the assessment of the complete DNA sequence of a person’s entire genome. For instance, Nucleus Genomics, an American genetic analysis provider, unveiled a DNA analysis offering in March 2024. This platform provides individuals with a more profound comprehension of their genetic predispositions, enabling them to make knowledgeable decisions regarding their health and wellness. Leveraging advanced technology and exceptional genetic counseling services, Nucleus Genomics is poised to transform the genetic testing field, bringing whole-genome sequencing directly to individuals and revolutionizing genomic medicine.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Regions Are Driving Growth in the Neurogenetic Testing Market?

North America was the largest region in the neurogenetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16131

This Report Delivers Insight On:

1. How big is the neurogenetic testing market, and how is it changing globally?

2. Who are the major companies in the neurogenetic testing market, and how are they performing?

3. What are the key opportunities and risks in the neurogenetic testing market right now?

4. Which products or customer segments are growing the most in the neurogenetic testing market?

5. What factors are helping or slowing down the growth of the neurogenetic testing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model